Indium111 antimyosin for the detection of leiomyosarcoma and rhabdomyosarcoma
Identifieur interne : 000538 ( Main/Exploration ); précédent : 000537; suivant : 000539Indium111 antimyosin for the detection of leiomyosarcoma and rhabdomyosarcoma
Auteurs : RBID : ISTEX:259_1988_Article_BF00252619.pdfEnglish descriptors
- KwdEn :
Abstract
111In-antimyosin monoclonal antibody complex passes through damaged myocardial cell membranes and binds to the intracellular myosin. Normal myocardial and other muscle cells show no uptake.Rhabdomyosarcoma and Leiomyosarcoma cells also contain intracellular myosin.and the cell membrane permeability is greater than normal. Significant uptake of 111In-antimyosin was observed in patient with Leiomyosarcoma and Rhabdomyosarcoma suggesting that the reagent has a potential for the in vivo detection of these tumour types. Tumour to background ratios of 10:1 were measured in one case and in view of the fact that the site of accumulation is intracellular, antimyosin may have a potential as a carrier for therapeutic agents.
DOI: 10.1007/BF00252619
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Indium111 antimyosin for the detection of leiomyosarcoma and rhabdomyosarcoma</title><author><name>P. H. Cox</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam</wicri:regionArea><wicri:noRegion>Rotterdam</wicri:noRegion></affiliation></author><author><name>J. Verweij</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical Oncology, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam</wicri:regionArea><wicri:noRegion>Rotterdam</wicri:noRegion></affiliation></author><author><name>M. Pillay</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam</wicri:regionArea><wicri:noRegion>Rotterdam</wicri:noRegion></affiliation></author><author><name>G. Stoter</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical Oncology, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam</wicri:regionArea><wicri:noRegion>Rotterdam</wicri:noRegion></affiliation></author><author><name>D. Schonfeld</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam</wicri:regionArea><wicri:noRegion>Rotterdam</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1988_Article_BF00252619.pdf</idno><date when="1988">1988</date><idno type="doi">10.1007/BF00252619</idno><idno type="wicri:Area/Main/Corpus">000799</idno><idno type="wicri:Area/Main/Curation">000799</idno><idno type="wicri:Area/Main/Exploration">000538</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimyosin</term><term>Immunoscintigraphy</term><term>Indium</term><term>Leiomyosarcoma</term><term>Rhabdomyosarcoma</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">111In-antimyosin monoclonal antibody complex passes through damaged myocardial cell membranes and binds to the intracellular myosin. Normal myocardial and other muscle cells show no uptake.Rhabdomyosarcoma and Leiomyosarcoma cells also contain intracellular myosin.and the cell membrane permeability is greater than normal. Significant uptake of 111In-antimyosin was observed in patient with Leiomyosarcoma and Rhabdomyosarcoma suggesting that the reagent has a potential for the in vivo detection of these tumour types. Tumour to background ratios of 10:1 were measured in one case and in view of the fact that the site of accumulation is intracellular, antimyosin may have a potential as a carrier for therapeutic agents.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="8ae8c5647ef410eaf2e2d8a99c1da451963f6db6"><titleInfo lang="eng"><title>Indium111 antimyosin for the detection of leiomyosarcoma and rhabdomyosarcoma</title></titleInfo><name type="personal"><namePart type="given">P. H.</namePart><namePart type="family">Cox</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands</affiliation></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Verweij</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Medical Oncology, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands</affiliation></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Pillay</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands</affiliation></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Stoter</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Medical Oncology, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands</affiliation></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Schonfeld</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, The Dr. Daniel den Hoed Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands</affiliation></name><typeOfResource>text</typeOfResource><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateCreated encoding="w3cdtf">1987-06-09</dateCreated><dateValid encoding="w3cdtf">2004-08-05</dateValid><copyrightDate encoding="w3cdtf">1988</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">111In-antimyosin monoclonal antibody complex passes through damaged myocardial cell membranes and binds to the intracellular myosin. Normal myocardial and other muscle cells show no uptake.Rhabdomyosarcoma and Leiomyosarcoma cells also contain intracellular myosin.and the cell membrane permeability is greater than normal. Significant uptake of 111In-antimyosin was observed in patient with Leiomyosarcoma and Rhabdomyosarcoma suggesting that the reagent has a potential for the in vivo detection of these tumour types. Tumour to background ratios of 10:1 were measured in one case and in view of the fact that the site of accumulation is intracellular, antimyosin may have a potential as a carrier for therapeutic agents.</abstract><subject lang="eng"><genre>Key words</genre><topic>Indium</topic><topic>Antimyosin</topic><topic>Rhabdomyosarcoma</topic><topic>Leiomyosarcoma</topic><topic>Immunoscintigraphy</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1988</partNumber><partNumber>Volume: 14</partNumber><partNumber>Number: 1</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1988-04-01</dateIssued><copyrightDate encoding="w3cdtf">1988</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 16</identifier><recordInfo><recordOrigin>Springer-Verlag, 1988</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF00252619</identifier><identifier type="matrixNumber">Art12</identifier><identifier type="local">BF00252619</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>50</start><end>52</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1988</recordOrigin><recordIdentifier>259_1988_Article_BF00252619.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000538 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000538 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1988_Article_BF00252619.pdf
|texte= Indium111 antimyosin for the detection of leiomyosarcoma and rhabdomyosarcoma
}}
| This area was generated with Dilib version V0.5.81. |  |